期刊文献+

兽用二氨基嘧啶类抗菌增效剂毒理学研究进展 被引量:4

Advances in Research on Toxicology of Veterinary Antibacterial Synergists
下载PDF
导出
摘要 二氨基嘧啶类抗菌增效剂是一类广谱、高效的药物,广泛应用于临床。综述二氨基嘧啶类抗菌增效剂的毒性作用,主要包括急性毒性、长期毒性、遗传毒性等,以期为评价其安全性,指导临床合理使用,开发新药,避免应用危害提供参考。 Diaminopyrimidine antibacterial synergist is a kind of high-efficiency,low-toxic drug,widely used in clinical practice. This paper reviews the toxicity of diaminopyrimidine antimicrobial synergists,mainly including acute toxicity,long-term toxicity and genetic toxicity,in order to provide a reference for evaluating their safety,guiding clinical rational use,developing new drugs and avoiding the harm of their application.
作者 郭京超 孙亚奇 刘振利 王旭 袁宗辉 GUO Jing-chao;SUN Ya-qi;LIU Zhen-li;WANG Xu;YUAN Zong-hui(National Reference Laboratory of Veterinary Drug Residues(HZAU),Key Laboratory of the Detection for Veterinary Drug Residues,Ministry of Agriculture,P.R China,Huazhong Agricultural University,Laboratory of Quality&Safety Risk Assessment for Livestock and Poultry Products(Wuhan),Ministry of Agriculture,P.R China,Huazhong Agricultural University,College of Veterinary Medicine,Huazhong Agricultural University,Wuhan 430070,China)
出处 《中国兽药杂志》 2019年第1期77-84,共8页 Chinese Journal of Veterinary Drug
基金 国家重点研发计划(2017YFD0501405)
关键词 甲氧苄啶 二甲氧苄啶 巴喹普林 奥美普林 艾地普林 毒性 trimethoprim diaveridine baquiloprim ormetoprim aditoprim toxicology
  • 相关文献

参考文献3

二级参考文献18

  • 1常明向,姚垂宇,刘小平,马卓,刘铭欣,黄阽云.黄连联用TMP抗菌作用的实验研究[J].中国中药杂志,1994,19(12):748-749. 被引量:17
  • 2[5]Manncke K, Springsklee M, Heizmann WR, et al. Sulbactam in Combination With Mezlocillin, Piperacillin or Cefotaxime: clinical And Bacteriological Findings In the Treatment of Serious Bacterial Infections. Int J Antimicrob Agents, 1996(Suppl): 547~554
  • 3[6]Marisa BM, Eneida SB, Stephen A, et al. Comarative in vitro antimicrobial susceptibilities of nosocomial isolates of acinetobacer baumannii and synergistic activities of nine antimicrobial combinations. Antimicrobial Agents an Chemotherapy, 1997, 41(5):881~885.
  • 4[7]Jimenez MME, Pachon J, Becerril B, et al. Treatment of multidrugresistant acinetobacer baumannii meningitis with ampicillin/sulbactam.Clin Infect Dis, 1997, 24(5):932~935.
  • 5[10]Joshi M, Bernstein J, Solomkin J, et al. Piperacillin-tazobactam plus tobramycin versus ceftazidimeplus tobramycin for the treatment of patients with nosocomial lower respiratory tract infections. J Antimicrob chemother, 1999, 43:389~397.
  • 6[11]Alvarez LF, Insausti OJ, Jorda MR, et al. Efficacy and tolerability of piperacillin-tazobactam versus ceftazidime in association with smikacin for treating nosocomial pneumonia in intensive care patients:a prospective randomized multicenter trial. Intensive Care Med. 2001,27(3):349~502.
  • 7[12]Coppi G, Mailland F. Immunopharmacological studies on PGT/1A, a new immunostimulating drug. Pharmacol Res, 1990, 22(Suppl 2):126~129.
  • 8[13]Migliorati G, Nicoletti I, Riccadi C. Immunomodulating activity of pidotimod. Arznei M Forsch/Drug Res, 1994, 12:1421~1424.
  • 9[14]Benetti GP, Fugazza L, Stramba BM, et al. Ex vivo evaluation of pidotimod activity on cell-mediated immunity. Arznei M Forsch/Drug Res, 1994, 12:1476~1479.
  • 10[15]Pugliese A, Biglino A, Uslenghi C, et al. Evaluation of the effect of pidotimod on the immune system. Int J Immunother, 1992, 8 (4):212~216.

共引文献8

同被引文献90

引证文献4

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部